Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Hepatocellular 37Liver Neoplasms 20Neoplasms 17Leukemia, Myeloid, Acute 13Neoplasm Metastasis 11Carcinoma, Renal Cell 9Carcinoma, Non-Small-Cell Lung 9Pancreatic Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Melanoma 7Breast Neoplasms 6Brain Neoplasms 6Unspecified Adult Solid Tumor, Protocol Specific 5Prostatic Neoplasms 5Multiple Myeloma 5Lung Neoplasms 5Kidney Neoplasms 5Recurrence 4Glioblastoma 4Colorectal Neoplasms 4Sarcoma 3Rectal Neoplasms 3Myelodysplastic Syndromes 3Leukemia, Promyelocytic, Acute 3Leukemia, Myelomonocytic, Acute 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Erythroblastic, Acute 3Leukemia, Eosinophilic, Acute 3

Interventions

verubulin 1trifluridine tipiracil drug combination 1irinotecan sucrosofate 1eribulin 1Temozolomide 1Sorafenib 1Irinotecan 1Interleukin-27 1Erlotinib Hydrochloride 1Azurin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Refractory Solid Tumors × Sorafenib × Clear all
NCT00759928 2014-07-02

PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors

SCRI Development Innovations, LLC

Phase 1 Completed
48 enrolled
Other solid neoplasm

Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡